Cargando…
Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
BACKGROUND: Data about real-world effects of combined therapy with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure (HF) with reduced ejection fraction (HFrEF) has not been widely reported. In this article, the benefits of dapagliflozin and sacubitril/valsartan respect t...
Autores principales: | Jiang, Juan, Gao, Jie, Zhang, Xiuzhen, Li, Yuanmin, Dang, Heqin, Liu, Yanlin, Chen, Wenwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073490/ https://www.ncbi.nlm.nih.gov/pubmed/37034349 http://dx.doi.org/10.3389/fcvm.2023.1097066 |
Ejemplares similares
-
Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real‐world study
por: Chen, Wenwen, et al.
Publicado: (2021) -
Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
por: Burgdorf, Christof, et al.
Publicado: (2021) -
Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea
por: Pelaia, Corrado, et al.
Publicado: (2022) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Pascual-Figal, Domingo, et al.
Publicado: (2021) -
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)